tiprankstipranks
RedHill Biopharma (RDHL)
NASDAQ:RDHL

RedHill Biopharma (RDHL) Financial Statements

736 Followers

RedHill Biopharma Financial Overview

RedHill Biopharma's market cap is currently ―. The company's EPS TTM is $-3.159; its P/E ratio is -0.17; RedHill Biopharma is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue-$ 17.55M$ 18.35M$ 18.24M$ 22.07M
Gross Profit-$ 8.10M$ 9.35M$ 10.20M$ 2.74M
EBIT-$ -3.92M$ -7.50M$ -13.23M$ -20.78M
EBITDA-$ -1.83M$ -5.58M$ -11.09M$ -9.59M
Net Income Common Stockholders-$ -35.70M$ -11.71M$ -17.14M$ -24.37M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 15.00K$ 15.22M$ 27.00M$ 28.86M$ 38.00M
Total Assets$ 158.87M$ 157.19M$ 167.97M$ 167.05M$ 181.19M
Total Debt$ 7.47M$ 120.83M$ 93.65M$ 95.01M$ 87.81M
Net Debt$ 7.46M$ 105.61M$ 66.64M$ 66.15M$ 49.81M
Total Liabilities$ 207.27M$ 203.22M$ 179.91M$ 172.29M$ 172.31M
Stockholders Equity$ -51.23M$ -46.03M$ -11.94M$ -5.24M$ 8.88M
Cash Flow-
Free Cash Flow-$ -6.05M$ -16.74M$ -4.17M$ -14.86M
Operating Cash Flow-$ -6.03M$ -16.58M$ -4.16M$ -14.86M
Investing Cash Flow-$ -22.00K$ -163.00K$ 8.49M$ 3.50M
Financing Cash Flow-$ -5.72M$ 14.92M$ -4.94M$ 17.57M
Currency in USD

RedHill Biopharma Earnings and Revenue History

RedHill Biopharma Debt to Assets

RedHill Biopharma Cash Flow

RedHill Biopharma Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis